Scarica l'app Stockscreener
8.48
2.64%
0.2183
Dopo l'orario di chiusura:
8.49
0.010
+0.12%
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
How dovish Fed policy supports ProMIS Neurosciences Inc. (23J0) stockPortfolio Return Report & Reliable Intraday Trade Plans - ulpravda.ru
ProMIS Neurosciences regains Nasdaq compliance - MSN
ProMIS Neurosciences to execute 1-for-25 reverse stock split - MSN
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Guidance Update: Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansionWeekly Profit Summary & Community Consensus Trade Signals - Улправда
Will ProMIS Neurosciences Inc. (23J0) stock see valuation expansion2025 Volatility Report & Daily Entry Point Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. (23J0) stock could outperform next yearQuarterly Trade Summary & Consistent Profit Trade Alerts - Улправда
Why ProMIS Neurosciences Inc. stock appeals to dividend seekers2025 Volume Leaders & Fast Momentum Stock Entry Tips - DonanımHaber
Why ProMIS Neurosciences Inc. stock remains on watchlistsGold Moves & Safe Capital Growth Plans - DonanımHaber
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial By Investing.com - Investing.com South Africa
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzh - GuruFocus
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial - Investing.com
ProMIS Neurosciences exceeds target enrollment in Precise-AD phase 1b clinical trial - marketscreener.com
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease - The Manila Times
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ... - Caledonian Record
About Us - FinancialContent
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule - Investing.com Australia
ProMIS Neurosciences Regains Nasdaq Compliance - TipRanks
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
ProMIS Neurosciences Announces Third Quarter 2019 Results - PR Newswire
ProMIS Neurosciences announces publication highlighting PMN310 - MSN
Cash per share of ProMIS Neurosciences Inc. – DUS:23J - TradingView — Track All Markets
ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com - Investing.com Nigeria
ProMIS Neurosciences shareholders approve share consolidation proposal - Investing.com
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - The Manila Times
ProMIS Neurosciences Announces New Peer-Reviewed - GlobeNewswire
Fortrea (NASDAQ:FTRE) & Promis Neurosciences (NASDAQ:PMN) Head-To-Head Review - Defense World
ProMIS Neurosciences: Buy Rating Backed by Innovative EpiSelect™ Platform and Promising PMN310 Candidate - TipRanks
Pretax income of ProMIS Neurosciences Inc. – BER:23J - TradingView
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
Can ProMIS Neurosciences Inc. (23J0) stock sustain margin levelsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
HC Wainwright Has Strong Forecast for PMN FY2025 Earnings - Defense World
How strong is ProMIS Neurosciences Inc. (23J0) stock earnings growth2025 Institutional Moves & Weekly Breakout Watchlists - Newser
How geopolitical risks impact ProMIS Neurosciences Inc. (23J0) stock2025 Market Trends & Long-Term Growth Stock Strategies - Newser
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s - MSN
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Why hedge funds are buying ProMIS Neurosciences Inc. stockWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
symbol__ Stock Quote Price and Forecast - CNN
ProMIS Neurosciences stock rises after promising Alzheimer’s research data By Investing.com - Investing.com Australia
HC Wainwright & Co. Maintains ProMIS Neurosciences (PMN) Buy Recommendation - Nasdaq
ProMIS Neurosciences Inc (23J0.DU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
PMN: HC Wainwright & Co. Raises Price Target and Maintains Buy R - GuruFocus
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. W - GuruFocus
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):